MarketCap
Facebook
X
Telegram
Avidity Biosciences Balance Sheet 2025-2011 | RNA
Brief balance sheet overview of Avidity Biosciences
The comparison uses five available annual reports from the 2021–2025 interval.
The asset base grew from $427.6 million to $2 billion, or +357.9%. Average annual growth of roughly 46.3% was strong.
Asset growth of +357.9% came with a +483.9% rise in liabilities. Financial leverage became more prominent.
Equity funds 86.2% of assets versus 89.2% initially. This creates a conservative balance sheet structure.
The balance sheet holds more cash than interest-bearing debt; net debt is -$333.3 million, indicating minimal leverage.
Cash equals 19.5% of the balance sheet, compared with 75% five periods ago. This is the readily available cushion.
The accumulated result is -$1.6 billion and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
What the balance sheet shows
Avidity Biosciences's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Avidity Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-333 M | -213 M | -176 M | -330 M | -309 M | - | -90 M | 7.23 M | - | - | - | - | - | - | - |
Long Term Debt |
45.3 M | 2.96 M | 6.21 M | 7.58 M | 9.96 M | - | 1.77 M | 7.58 M | - | - | - | - | - | - | - |
Long Term Debt Current |
3.94 M | 3.84 M | 3.64 M | 3.1 M | 1.77 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 152 M | 40.5 M | - | - | - | - | - | - | - |
Total Current Liabilities |
195 M | 98 M | 80.7 M | 51.9 M | 29.7 M | 14.6 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
269 M | 139 M | 128 M | 60.7 M | 46.2 M | 27.7 M | 162 M | 45.1 M | - | - | - | - | - | - | - |
Deferred Revenue |
21.6 M | 21 M | 28.4 M | 5.04 M | 4.86 M | 3.69 M | 3.84 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.58 B | -893 M | -571 M | -359 M | -185 M | -66.5 M | -22.2 M | -41.6 M | - | - | - | - | - | - | - |
Total Assets |
1.96 B | 1.56 B | 629 M | 639 M | 428 M | 334 M | 96.9 M | 3.98 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
383 M | 220 M | 185 M | 341 M | 321 M | 322 M | - | - | - | - | - | - | - | - | - |
Book Value |
1.69 B | 1.42 B | 501 M | 578 M | 381 M | 306 M | -65.4 M | -41.1 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.69 B | 1.42 B | 501 M | 578 M | 381 M | 306 M | -65.4 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Avidity Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
46 M | 1.21 M | 2.09 M | 2.96 M | 3.8 M | 4.62 M | 5.42 M | 6.21 M | 6.98 M | 6.36 M | 6.98 M | 7.58 M | 8.18 M | 8.75 M | 9.35 M | 9.96 M | 877 K | 914 K | 951 K | 938 K | - | - | 938 K | 1.77 M | 1.77 M | 1.77 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
248 M | 176 M | 130 M | 139 M | 137 M | 126 M | 121 M | 128 M | 55.7 M | 51.6 M | 55.1 M | 60.7 M | 53.6 M | 46.4 M | 45.4 M | 46.2 M | 31 M | 26 M | 28.6 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M | 27.5 M | 27.5 M | 27.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
19.1 M | 13.5 M | 14 M | 21 M | 19.7 M | 26.7 M | 26.1 M | 28.4 M | 1.97 M | 3.81 M | 5.06 M | 5.04 M | 5.45 M | 5.38 M | 5.31 M | 4.86 M | 4.26 M | 4.5 M | 4.36 M | 3.69 M | 3.69 M | 3.69 M | 3.69 M | 3.84 M | 3.84 M | 3.84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.34 B | -1.17 B | -1.01 B | -893 M | -791 M | -710 M | -640 M | -571 M | -510 M | -458 M | -411 M | -359 M | -308 M | -264 M | -219 M | -185 M | -146 M | -117 M | -90.4 M | -66.5 M | -66.5 M | -66.5 M | -66.5 M | -22.2 M | -22.2 M | -22.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.13 B | 1.37 B | 1.46 B | 1.56 B | 1.64 B | 1.35 B | 951 M | 629 M | 573 M | 611 M | 614 M | 639 M | 431 M | 421 M | 421 M | 428 M | 426 M | 291 M | 315 M | 334 M | 334 M | 334 M | 334 M | 96.9 M | 96.9 M | 96.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
350 M | 244 M | 254 M | 220 M | 373 M | 579 M | 472 M | 185 M | 85.9 M | 154 M | 119 M | 340 M | 144 M | 125 M | 140 M | 320 M | 410 M | 276 M | 301 M | 321 M | 321 M | 321 M | 321 M | 94.6 M | 94.6 M | 94.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.89 B | 1.19 B | 1.33 B | 1.42 B | 1.5 B | 1.22 B | 831 M | 501 M | 517 M | 559 M | 559 M | 578 M | 377 M | 374 M | 376 M | 381 M | 395 M | 264 M | 286 M | 306 M | 306 M | 306 M | 306 M | 69.4 M | 69.4 M | 69.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.89 B | 1.19 B | 1.33 B | 1.42 B | 1.5 B | 1.22 B | 831 M | 501 M | 517 M | 559 M | 559 M | 578 M | 377 M | 374 M | 376 M | 381 M | 395 M | 264 M | 286 M | 306 M | 306 M | 306 M | 306 M | -65.4 M | -65.4 M | -65.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Avidity Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
